keyword
https://read.qxmd.com/read/38663918/identification-and-validation-of-an-anoikis-related-genes-signature-for-prognostic-implication-in-papillary-thyroid-cancer
#21
JOURNAL ARTICLE
Runyu Zhao, Yingying Lu, Zhihan Wan, Peipei Qiao, Liyun Yang, Yi Zhang, Shuixian Huang, Xiaoping Chen
Thyroid cancer, notably papillary thyroid cancer (PTC), is a global health concern with increasing incidence. Anoikis, a regulator of programmed cell death, is pivotal in normal physiology and, when dysregulated, can drive cancer progression and metastasis. This study explored the impact of anoikis on PTC prognosis. Analyzing data from GEO, TCGA, and GeneCards, we identified a prognostic signature consisting of six anoikis-related genes (ARGs): EZH2, PRKCQ, CD36, INHBB, TDGF1, and MMP9. This signature independently predicted patient outcomes, with high-risk scores associated with worse prognoses...
April 24, 2024: Aging
https://read.qxmd.com/read/38659289/basal-differentiation-and-expression-status-of-sox2-and-klf4-in-basal-layers-are-prognostic-factors-for-disease-specific-survival-in-oral-squamous-cell-carcinoma
#22
JOURNAL ARTICLE
Kazuhiro Murakami, Tomoko Kamiakito, Hirotoshi Kawata, Koki Kosami, Takeo Nakaya, Tadahide Noguchi, Yoshiyuki Mori, Akira Tanaka
BACKGROUND: Basal differentiation in oral squamous cell carcinoma is usually detected at invasive sites. However, its significance as a prognostic value has been poorly investigated. METHODS: COL17 was selected as a basal differentiation marker because of its stable expression in the basal-like cells of oral squamous cell carcinoma. Sixty-five cases of oral squamous cell carcinoma were subclassified into COL17-high (30 cases) and -low (35 cases) types, and the prognostic value was analyzed by Cox regression analysis...
April 24, 2024: Journal of Oral Pathology & Medicine
https://read.qxmd.com/read/38658543/ezh2-mutations-in-follicular-lymphoma-distort-h3k27me3-profiles-and-alter-transcriptional-responses-to-prc2-inhibition
#23
JOURNAL ARTICLE
Pierre Romero, Laia Richart, Setareh Aflaki, Ambre Petitalot, Megan Burton, Audrey Michaud, Julien Masliah-Planchon, Frédérique Kuhnowski, Samuel Le Cam, Carlos Baliñas-Gavira, Céline Méaudre, Armelle Luscan, Abderaouf Hamza, Patricia Legoix, Anne Vincent-Salomon, Michel Wassef, Daniel Holoch, Raphaël Margueron
Mutations in chromatin regulators are widespread in cancer. Among them, the histone H3 lysine 27 methyltransferase Polycomb Repressive Complex 2 (PRC2) shows distinct alterations according to tumor type. This specificity is poorly understood. Here, we model several PRC2 alterations in one isogenic system to reveal their comparative effects. Focusing then on lymphoma-associated EZH2 mutations, we show that Ezh2Y641F induces aberrant H3K27 methylation patterns even without wild-type Ezh2, which are alleviated by partial PRC2 inhibition...
April 24, 2024: Nature Communications
https://read.qxmd.com/read/38656651/a-novel-t-x-21-p11-4-q22-12-translocation-adds-to-the-role-of-bcor-and-runx1-in-myelodysplastic-syndromes-and-acute-myeloid-leukemias
#24
JOURNAL ARTICLE
Elena Mavridou, Anair Graciela Lema Fernandez, Carlotta Nardelli, Valentina Pierini, Martina Quintini, Silvia Arniani, Danika Di Giacomo, Barbara Crescenzi, Caterina Matteucci, Constantina Sambani, Cristina Mecucci
In myeloid neoplasms, both fusion genes and gene mutations are well-established events identifying clinicopathological entities. In this study, we present a thus far undescribed t(X;21)(p11.4;q22.12) in five cases with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The translocation was isolated or accompanied by additional changes. It did not generate any fusion gene or gene deregulation by aberrant juxtaposition with regulatory sequences. Molecular analysis by targeted next-generation sequencing showed that the translocation was accompanied by at least one somatic mutation in TET2, EZH2, RUNX1, ASXL1, SRSF2, ZRSR2, DNMT3A, and NRAS genes...
April 2024: Genes, Chromosomes & Cancer
https://read.qxmd.com/read/38652219/melk-aggravates-lung-adenocarcinoma-by-regulating-ezh2-ubiquitination-and-h3k27me3-histone-methylation-of-lats2
#25
JOURNAL ARTICLE
Hui Yu, Xianrong Xu, Lirong Zhu, Shengjie Chen, Jincheng He
We tried to elucidate the possible roles of maternal embryonic leucine pull chain kinase (MELK) in lung adenocarcinoma (LUAD) growth and metastasis. Differentially expressed genes in LUAD samples were analysed by the GEPIA database. Clinical tissue samples and cells were collected for MELK, EZH2 and LATS2 expression determination. Co-IP assay was used to verify the interaction between EZH2 and MELK; CHX tracking assay and ubiquitination assay detected the degradation of MELK on EZH2 ubiquitination. ChIP assay detected the enrichment of EZH2 and H3K27me3 on the LATS2 promoter region...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38651271/development-of-an-efficient-liposomal-dox-delivery-formulation-for-hcc-therapy-by-targeting-ck2%C3%AE
#26
JOURNAL ARTICLE
Ruixia Zhao, Sinan Cheng, Xue Bai, Danying Zhang, Hongming Fang, Wanlin Che, Wenxuan Zhang, Yujuan Zhou, Wei Duan, Qiumin Liang, Li Xiao, Guochao Nie, Yingchun Hou
Hepatocellular carcinoma (HCC) is a digestive tract cancer with high mortality and poor prognosis, especially in China. Current chemotherapeutic drugs lead to poor prognosis, low efficacy, and high side effects due to weak targeting specificity and rapidly formed multidrug resistance (MDR). Based on the previous studies on the doxorubicin (DOX) formulation for cancer targeting therapy, we developed a novel DOX delivery formulation for the targeting chemotherapy of HCC and DOX resistant HCC. HCSP4 was previously screened and casein kinase 2α (CK2α) was predicted as its specific target on HCC cells in our lab...
April 2024: Biotechnology Journal
https://read.qxmd.com/read/38651182/snhg1-knockdown-promotes-osteogenic-differentiation-of-hdfscs-through-anti-oxidative-stress-mediated-by-autophagy
#27
JOURNAL ARTICLE
Lidi Deng, Liping Wu, Dongru Chen, Yang Cao
The long noncoding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) plays a crucial role in tumorigenesis and is frequently employed as a prognostic biomarker. However, its involvement in the osteogenic differentiation of oral stem cells, particularly human dental follicle stem cells (hDFSCs), remains unclear. Our investigation revealed that the absence of SNHG1 enhances the osteogenic differentiation of hDFSCs. Furthermore, the downregulation of SNHG1 induces autophagy in hDFSCs, leading to a reduction in intracellular oxidative stress levels...
April 23, 2024: Journal of Cellular Physiology
https://read.qxmd.com/read/38646788/long-noncoding-rna-neat1-enhances-phenotypic-and-osteogenic-switching-of-vascular-smooth-muscle-cells-in-atherosclerosis-via-scaffolding-ezh2
#28
JOURNAL ARTICLE
Chengye Yin, Zhuowang Ge, Jiali Yuan, Yuhan Chen, Yong Tang, Yin Xiang, Yachen Zhang
Atherosclerosis (AS) is a significant contributor to cardio-cerebrovascular ischemia diseases, resulting in high mortality rates worldwide. During AS, vascular smooth muscle cells (VSMCs) play a crucial role in plaque formation by undergoing phenotypic and osteogenic switching. Long noncoding RNA nuclear paraspeckle assembly transcript 1 (NEAT1) has previously been identified as a nuclear regulator that promotes tumorigenesis and metastasis, but its role in regulating VSMCs in AS remains unclear. Our study aimed to investigate the biological functions and specific mechanisms of NEAT1 in regulating VSMCs in AS...
April 22, 2024: American Journal of Physiology. Cell Physiology
https://read.qxmd.com/read/38645261/increased-ezh2-function-in-regulatory-t-cells-promotes-their-capacity-to-suppress-autoimmunity-by-driving-effector-differentiation-prior-to-activation
#29
Janneke G C Peeters, Stephanie Silveria, Merve Ozdemir, Srinivas Ramachandran, Michel DuPage
UNLABELLED: The immunosuppressive function of regulatory T (Treg) cells is essential for maintaining immune homeostasis. Enhancer of zeste homolog 2 (EZH2), a histone H3 lysine 27 (H3K27) methyltransferase, plays a key role in maintaining Treg cell function upon CD28 co-stimulation, and Ezh2 deletion in Treg cells causes autoimmunity. Here we assessed whether increased EZH2 activity in Treg cells would improve Treg cell function. Using an Ezh2 gain-of-function mutation, Ezh2 Y641F , we found that Treg cells expressing Ezh2 Y641F displayed an increased effector Treg phenotype and were poised for improved homing to organ tissues...
April 10, 2024: bioRxiv
https://read.qxmd.com/read/38644693/chronic-neutrophilic-leukemia-and-atypical-chronic-myeloid-leukemia-2024-update-on-diagnosis-genetics-risk-stratification-and-management
#30
REVIEW
Natasha Szuber, Attilio Orazi, Ayalew Tefferi
Chronic neutrophilic leukemia (CNL) is a rare BCR::ABL1-negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic "[MDS]/MPN with neutrophilia" per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death...
April 21, 2024: American Journal of Hematology
https://read.qxmd.com/read/38644473/protac-ezh2-degrader-1-overcomes-the-resistance-of-podophyllotoxin-derivatives-in-refractory-small-cell-lung-cancer-with-leptomeningeal-metastasis
#31
JOURNAL ARTICLE
Min-Xing Shi, Xi Ding, Liang Tang, Wei-Jun Cao, Bo Su, Jie Zhang
BACKGROUND: Leptomeningeal metastasis (LM) of small cell lung cancer (SCLC) is a highly detrimental occurrence associated with severe neurological disorders, lacking effective treatment currently. Proteolysis-targeting chimeric molecules (PROTACs) may provide new therapeutic avenues for treatment of podophyllotoxin derivatives-resistant SCLC with LM, warranting further exploration. METHODS: The SCLC cell line H128 expressing luciferase were mutated by MNNG to generate H128-Mut cell line...
April 22, 2024: BMC Cancer
https://read.qxmd.com/read/38642703/targeting-eed-as-a-key-prc2-complex-mediator-toward-novel-epigenetic-therapeutics
#32
REVIEW
Qichao Bao, Anil Kumar, Daqing Wu, Jia Zhou
EED within the PRC2 complex is crucial for chromatin regulation, particularly in tumor development, such that its inhibition is a promising epigenetic therapeutic strategy. Significant advancement in PRC2 inhibitor development has been achieved with an approved EZH2 inhibitor in the market and with others in clinical trials. However, current EZH2 inhibitors are limited to specific blood cancers and encounter therapeutic resistance. EED stabilizes PRC2 and enhances its activity through unique allosteric mechanisms, thereby acting as both a scaffold protein and a recognizer of H3K27me3 making it an attractive drug target...
April 18, 2024: Drug Discovery Today
https://read.qxmd.com/read/38640588/discovery-of-novel-pyridone-benzamide-derivatives-possessing-a-1-methyl-2-benzimidazolinone-moiety-as-potent-ezh2-inhibitors-for-the-treatment-of-b-cell-lymphomas
#33
JOURNAL ARTICLE
Di Wu, Xiaoyi Zeng, Yuanhao Zhao, Mingze Qin, Ping Gong
Enhancer of zeste homolog 2 (EZH2) is a promising therapeutic target for diffuse large B-cell lymphoma. In this study, based on the binding model of 1 (tazemetostat) with polycomb repressive complex 2 (PRC2), we designed and synthesized a series of tazemetostat analogs bearing a 1-methyl-2-benzimidazolinone moiety to improve the inhibitory activity of EZH2 wild-type (WT) and Y641 mutants and enhance metabolic stability. After the assessment of the structure-activity relationship at enzymatic and cellular levels, compound N40 was identified...
April 14, 2024: Bioorganic & Medicinal Chemistry
https://read.qxmd.com/read/38635107/mechanisms-of-ferroptosis-related-genes-in-gallbladder-cancer-based-on-bioinformatics-analysis
#34
JOURNAL ARTICLE
Miao Li, Hang Shi, Jing Dong, Ning Lu, Jinjie Lou, Yangbo Xu
Gallbladder Cancer (GBC) is a lethal malignancy with limited treatment options and poor prognosis. Recent studies have emphasized the role of ferroptosis, a regulated form of cell death, in various cancers, including GBC. We applied bioinformatics methodologies on four GBC datasets to identify differentially expressed genes (DEGs). An intersection of DEGs from the four datasets with ferroptosis and GBC-associated genes was done to identify key ferroptosis-related genes in GBC. GSVA pathway enrichment analysis and immune cell infiltration assessment were conducted to explore their functional roles and interactions...
April 18, 2024: Molecular Biotechnology
https://read.qxmd.com/read/38623968/ezh2-suppresses-ferroptosis-in-hepatocellular-carcinoma-and-reduces-sorafenib-sensitivity-through-epigenetic-regulation-of-tfr2
#35
JOURNAL ARTICLE
Yongwei Lai, Xu Han, Bo Xie, Yan Xu, Zhengyi Yang, Didi Wang, Wei Li, Yaohong Xie, Wenqi Song, Xiaohong Zhang, Jia Qi Xia, Pengxia Zhang
Enhancing sensitivity to sorafenib can significantly extend the duration of resistance to it, offering substantial benefits for treating patients with hepatocellular carcinoma (HCC). However, the role of ferroptosis in influencing sorafenib sensitivity within HCC remains pivotal. The enhancer of zeste homolog 2 (EZH2) plays a significant role in promoting malignant progression in HCC, yet the relationship between ferroptosis, sorafenib sensitivity, and EZH2 is not entirely clear. Bioinformatic analysis indicates elevated EZH2 expression in HCC, predicting an unfavorable prognosis...
April 16, 2024: Cancer Science
https://read.qxmd.com/read/38617973/control-of-endothelial-cell-function-and-arteriogenesis-by-meg3-ezh2-epigenetic-regulation-of-integrin-expression
#36
JOURNAL ARTICLE
Hywel Dunn-Davies, Tatiana Dudnakova, Antonella Nogara, Julie Rodor, Anita C Thomas, Elisa Parish, Philippe Gautier, Alison Meynert, Igor Ulitsky, Paolo Madeddu, Andrea Caporali, Andrew Baker, David Tollervey, Tijana Mitić
Epigenetic processes involving long non-coding RNAs regulate endothelial gene expression. However, the underlying regulatory mechanisms causing endothelial dysfunction remain to be elucidated. Enhancer of zeste homolog 2 (EZH2) is an important rheostat of histone H3K27 trimethylation (H3K27me3) that represses endothelial targets, but EZH2 RNA binding capacity and EZH2:RNA functional interactions have not been explored in post-ischemic angiogenesis. We used formaldehyde/UV-assisted crosslinking ligation and sequencing of hybrids and identified a new role for maternally expressed gene 3 (MEG3)...
June 11, 2024: Molecular Therapy. Nucleic Acids
https://read.qxmd.com/read/38616211/what-is-new-in-acute-myeloid-leukemia-classification
#37
REVIEW
Hee Sue Park
Recently, the International Consensus Classification (ICC) and the 5th edition of the World Health Organization classification (WHO2022) introduced diagnostically similar yet distinct approaches, which has resulted in practical confusion. This review compares these classification systems for acute myeloid leukemia (AML), building up on the revised 4th edition of WHO (WHO2016). Both classifications retain recurrent genetic abnormalities as a primary consideration. However, they differ in terms of blast threshold...
April 15, 2024: Blood Research
https://read.qxmd.com/read/38606590/unlocking-adult-t-cell-leukemia-lymphoma-s-epigenetic-secrets-delving-into-the-mechanism-and-impact-of-ezh1-2-inhibition
#38
JOURNAL ARTICLE
Paniz Tavakoli Shirazi, Megan J Bywater
Epigenetic modifications, particularly through methylation of DNA packaging histones, play a pivotal role in controlling gene expression. Aberrant patterns of histone methylation have been associated with the development and progression of hematological malignancies. Unraveling the impact of aberrant histone marks on gene expression and leukemogenesis has spurred a concerted effort to develop clinically effective epigenetic therapies. In malignancies associated with the accumulation of histone H3 lysine trimethylation (H3K27me3), one such intervention involves preventing the deposition of this repressive histone mark by inhibiting the histone-modifying enzymes EZH1 and EZH2...
April 12, 2024: Immunology and Cell Biology
https://read.qxmd.com/read/38600608/polycomb-repressive-complex-2-and-its-core-component-ezh2-potential-targeted-therapeutic-strategies-for-head-and-neck-squamous-cell-carcinoma
#39
REVIEW
Yuxi Cheng, Zhengzheng Song, Xiaodan Fang, Zhangui Tang
The polycomb group (PcG) comprises a set of proteins that exert epigenetic regulatory effects and play crucial roles in diverse biological processes, ranging from pluripotency and development to carcinogenesis. Among these proteins, enhancer of zeste homolog 2 (EZH2) stands out as a catalytic component of polycomb repressive complex 2 (PRC2), which plays a role in regulating the expression of homologous (Hox) genes and initial stages of x chromosome inactivation. In numerous human cancers, including head and neck squamous cell carcinoma (HNSCC), EZH2 is frequently overexpressed or activated and has been identified as a negative prognostic factor...
April 10, 2024: Clinical Epigenetics
https://read.qxmd.com/read/38600314/genome-wide-dna-methylation-analysis-of-blastic-plasmacytoid-dendritic-cell-neoplasm-identifies-distinct-molecular-features
#40
JOURNAL ARTICLE
Axel Künstner, Julian Schwarting, Hanno M Witte, Pengwei Xing, Veronica Bernard, Stephanie Stölting, Philipp Lohneis, Florian Janke, Maede Salehi, Xingqi Chen, Kathrin Kusch, Holger Sültmann, Emil Chteinberg, Anja Fischer, Reiner Siebert, Nikolas von Bubnoff, Hartmut Merz, Hauke Busch, Alfred C Feller, Niklas Gebauer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs. We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45 BPDCN patients supplemented by WES and RNA-seq as well as ATAC-seq on selected cases. We determined the BPDCN DNA methylation profile and observed a dramatic loss of DNA methylation during malignant transformation from early and mature DCs towards BPDCN...
April 10, 2024: Leukemia
keyword
keyword
8427
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.